SK Biopharm Holds POA Meeting in the US with All Sales Personnel Gathered

SK Biopharm announced on the 24th that its U.S. subsidiary, SK Life Sciences, is holding the '2023 Plan of Action (POA)' meeting in Dallas, USA, from the 21st to the 24th (local time).

Lee Dong-hoon, President of SK Biopharm, is speaking at the '2023 Plan of Action' meeting held in Dallas, USA.
[Photo by SK Biopharm]

Since 2020, SK Life Sciences has been hosting the Plan of Action meeting in the U.S. for the fourth consecutive year. The Plan of Action meeting is an event held by companies operating sales networks in the pharmaceutical and biotech industries in the U.S., aimed at training sales representatives and managers and delivering key information.

At this Plan of Action meeting, attended by about 130 employees, President Lee Dong-hoon will share the achievements and vision of the epilepsy drug Cenobamate (U.S. product name Xcopri) with local staff, review the first half performance, and discuss maximizing sales efforts for the second half of the year.

SK Biopharm is the first and only Korean pharmaceutical company to have a direct sales organization through its U.S. subsidiary and is actively conducting sales activities in the U.S. market. Up to the first half of 2023, Cenobamate recorded sales of 137.8 billion KRW in the U.S., growing more than 45% compared to the same period last year.

Through this Plan of Action meeting, SK Biopharm aims to enhance organizational focus and further accelerate growth momentum in the second half of the year.

In his CEO presentation on the 23rd, President Lee Dong-hoon said, "Cenobamate, with its innovative efficacy, is effectively targeting the U.S. market, and the efforts of the sales organization in the U.S. to achieve high goals are showing results. Through this meeting, we will set new initiatives for the second half and efficiently reallocate resources to further boost growth."

SK Biopharm plans to maximize synergy by adding products through the local sales network at the point when Cenobamate achieves the number one market share in the prescription area, alongside its growth.